Overview
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers
Status:
Completed
Completed
Trial end date:
2011-11-01
2011-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of ascending doses administered once daily for 14 days in healthy volunteers.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Biogen
Pfizer
Criteria
Inclusion Criteria:- Healthy male and/or female subjects of non-child bearing potential Body Mass Index
(BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease
- History of seizures or of a condition with risk of seizures
- Pregnant or nursing females, and females of child bearing potential